# EDGAR Filing Document

**Accession Number:** 0001756594
**File Stem:** 0001104659-23-000091
**Filing Date:** 2023-1
**Character Count:** 32361
**Document Hash:** abbb38ecb43b8eb802a810bdb44e7189
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-000091.hdr.sgml**: 20230103

**ACCESSION NUMBER**: 0001104659-23-000091

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 8

**CONFORMED PERIOD OF REPORT**: 20230103

**FILED AS OF DATE**: 20230103

**DATE AS OF CHANGE**: 20230103

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inventiva S.A.
- **CENTRAL INDEX KEY:** 0001756594
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39374
- **FILM NUMBER:** 23500244

**BUSINESS ADDRESS:**
- **STREET 1:** 50 RUE DE DIJON
- **CITY:** DAIX
- **STATE:** I0
- **ZIP:** 21121
- **BUSINESS PHONE:** 33380447500

**MAIL ADDRESS:**
- **STREET 1:** 50 RUE DE DIJON
- **CITY:** DAIX
- **STATE:** I0
- **ZIP:** 21121

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 6-K**

------

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**January 3, 2023**

**Commission File Number: 001-39374**

------

**Inventiva S.A.**

**(Translation of registrant's name into English)** 

------

**50 rue de Dijon**

**21121 Daix France**

**+33 3 80 44 75 00<br> (Address of principal executive office)**

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

⌧ Form 20-F ◻ Form 40-F

**Press Releases and Announcements**

On December 30, 2022, Inventiva S.A. ("Company") began mailing its proxy card ("Proxy Card") and Instructions for Beneficial Owners of American Depositary Shares ("Voting Instructions") to the beneficial owners of the Company's American Depositary Shares in connection with the Company's Ordinary and Extraordinary General Meeting ("General Meeting") that will be held on January 25, 2023 at 2 p.m., at Hôtel Oceania Le Jura - 14 avenue Foch - 21000 Dijon, France. A copy of the Proxy Card is attached to this Report on Form 6-K as Exhibit 99.1 and a copy of the Voting Instructions as Exhibit 99.2.

On January 3, 2023, the Company announced that the preparatory documents for the General Meeting (the "Preparatory Documents Announcement") will be available as of January 4, 2023 and issued the statement of total voting rights and shares forming the company's share capital as of December 19, 2022 (the "Statement of Voting Rights"). A copy of the Preparatory Documents Announcement is attached to this Report on Form 6-K as Exhibit 99.3 and a copy of the Statement of Voting Rights as Exhibit 99.4.

**Incorporation by reference**

This Report on Form 6-K, excluding Exhibits 99.1, 99.2, 99.3, and 99.4, shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-258369) of Inventiva S.A. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibits 99.1, 99.2, 99.3, and 99.4 to this Report are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](tm2233812d1_ex99-1.htm) | [Proxy Card.](tm2233812d1_ex99-1.htm) |
| [99.2](tm2233812d1_ex99-2.htm) | [Voting Instructions.](tm2233812d1_ex99-2.htm) |
| [99.3](tm2233812d1_ex99-3.htm) | [Preparatory Documents Announcement dated January 3, 2023.](tm2233812d1_ex99-3.htm) |
| [99.4](tm2233812d1_ex99-4.htm) | [Statement of Voting Rights dated January 3, 2023.](tm2233812d1_ex99-4.htm) |

---

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **Inventiva S.A.** | **Inventiva S.A.** | **Inventiva S.A.** |
| Date: January 3, 2023 | By: | /s/ Frédéric Cren | /s/ Frédéric Cren |
|  |  | Name | Frédéric Cren |
|  |  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2233812d1_ex99-1img001.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please separate carefully at the perforation and return just this portion in the envelope provided. Ordinary and Extraordinary General Meeting of Inventiva S.A. Ordinar y an d Extraordinar y Genera l Meetin g o f Inventiv a S.A. to be held January 25, 2023 Date: January 25, 2023 See Voting Instruction On Reverse Side. Please make your marks like this: Use pen only For Holders as of December 19, 2022 PLEASE REFER TO THE REVERSE SIDE FOR THE FULL TEXT OF THE RESOLUTIONS Agenda – Shareholders' Meeting of January 25, 2023 The Board of Directors recommends votin g D i i r n e c f t a o r v s or for all resolutions except for resolution #11. MAIL • Mark, sign and date your Voting Instruction Form. • Detach your Voting Instruction Form. Ordinary Genera l Meeting 1. Extraordinary General Shareholders' Meeting 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. On an ordinary basis 16. For Against Abstain • Return your Voting Instruction Form in the postage - paid envelope provided. All votes must be received by 12:00 PM Eastern Time January 18, 2023. OGM & EGM materials will be made available on the company's website as of January 4th, 2023 at www.inventivapharma.com PROXY TABULATOR FOR INVENTIVA S.A. P.O. BOX 8016 CARY, NC 27512 - 9903 EVENT # CLIENT # Authorized Signatures - This section must be completed for your instructions to be executed. Please Sign Here Please Date Above Please Sign Here Please Date Above Copyright© 2022 Mediant Communications Inc. All Rights Reserved  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2233812d1_ex99-1img002.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PROX Y TABULATO R FOR INVENTIV A S.A. P.O .. BO X 8016 CARY , N C 27512 - 9903 Inventiva S.A. Instructions to The Bank of New York Mellon, as Depositary (Must be received prior to 12:00 PM Eastern Time January 18, 2023) The undersigned Holder of American Depositary Receipts ("Receipts") of Inventiva S.A. (the "Company") hereby requests and instructs The Bank of New York Mellon, as Depositary, to vote or cause to be voted the number of ordinary shares represented by such Receipt(s) of the Company, registered in the name of the undersigned on the books of the Depositary as of the close of business December 19, 2022 at the Ordinary and Extraordinary General Meeting of Shareholders to be held on January 25, 2023. Notes: 1. Please direct the Depositary how to vote by placing an X in the box opposite the resolutions on the reverse side. 2. If no instructions are received, a discretionary proxy will be given to a person designated by the Company. A GEN D A Reading of the reports of the Board of Directors and the Statutory Auditor; Ordinary items 1. Ratification of the appointment (cooptation) of Ms. Lucy Lu to replace a resigning Director; Extraordinary items 2. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, with shareholders' preemptive subscription rights maintained; 3. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders' preempt ive subscription rights, by way of public offerings, excluding offers referred to in Article L.411 - 2 1° of the French Code monétaire et financier; 4. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders' preempt ive subscription rights, by way of public offerings referred to in Article L.411 - 2 1° of the French Code monétaire et financier; 5. Authorization to the Board of Directors to set the issuance price on the capital increases by way of public offerings, without shareholders' preemptive rights, pursuant to the terms and conditions set by the General Shareholders' Meeting, and up to the limit of 10% of the share capital; 6. Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, without shareholders' preemptive subscription rights; 7. Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares, immediately or in the future, reserved for certain specific categories of beneficiaries meeting specific characteristics within the framework of an equity financing agreement on the US market called "At - the - market" or "ATM", without shareholders' preemptive subscription rights; 8. Authorization to the Board of Directors to increase the number of securities to be issued as part of share capital increases with or without shareholders' preemptive subscription rights; 9. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares and securities giving access to the share capital of the Company, immediately or in the future, as part of a public exchange offer initiated by the Company; 10. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in consideration for contributio ns in kind up to a maximum of 10% of the share capital, excluding the case of a public exchange offer initiated by the Company; 11. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares o r securities giving access to the share capital of the Company immediately or in the future by the company reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Article L.3332 - 18 et seq. of the French Code du travail, without shareholders' preferential subscription rights; 12. Delegation of authority to the Board of Directors to increase the share capital of the Company by incorporating reserves, profit s or premiums; 13. Authorization to the Board of Directors to grant free shares to employees and/or certain corporate officers; 14. Authorization to the Board of Directors to grant share subscription and/or share purchase options to corporate officers and employees of the Company or companies of the group, entailing the waiver by shareholders of their preferential rights to subscribe for shares issued following the exercise of stock options; 15. Delegation of authority to the Board of Directors to decide on the issue of share subscription warrants, without shareholders' preemptive subscription rights, to the benefit of categories of persons; On an ordinary basis 16. Power for formalities.  |

---

## Exhibit 99.2

**Exhibit 99.2**

INVENTIVA S.A.

Ordinary and Extraordinary General Meeting of Inventiva S.A. to be held on

January 25, 2023

Instructions for beneficial owners of American Depositary Shares ("ADSs")

Beneficial owners of ADSs who wish to submit their votes in connection with the General Meeting of Inventiva to be held on January 25, 2023 should consult the voting instruction form delivered to them by The Bank of New York Mellon, as depositary, and the materials posted to the Shareholder Meeting section on the www.inventivapharma.com website as of January 4, 2023. Alternatively, you can submit a request for a free physical copy of the materials from Inventiva in writing at 50 rue de Dijon, DAIX (21121), France.

Beneficial Owners of ADSs have the opportunity to submit their votes by returning the completed voting form in the postage-paid envelope that accompanies their voting form. Beneficial Owners of ADSs are urged to consult their broker for further guidance on how to submit their votes.

## Exhibit 99.3

**Exhibit 99.3**

---

| | |
|:---|:---|
| ![](tm2233812d1_ex99-3img001.jpg) | **PRESS RELEASE** |

---

**Combined General Meeting of January 25, 2023**

**Availability of the preparatory documents** 

**Daix (France), Long Island City (New York, United States), January 3, 2023** – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of January 25, 2023.

Shareholders are invited to participate in the Combined General Meeting that will be held on January 25, 2023 at 2 p.m. at Hôtel Oceania Le Jura, 14 avenue Foch, 21000 Dijon (France).

The preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on how to attend and vote at the Combined General Meeting, was published in the *Bulletin des Annonces Légales Obligatoires* (BALO) n°151 of December 19, 2022 and a translation was filed with the Securities and Exchange Commission on December 19, 2022.

Information and documents pertaining to the Combined General Meeting are available in the Company's website (www.inventivapharma.com, section "Investors" / "Shareholder Meetings").

In accordance with articles R. 225-83 and R. 225-89 of the French Commercial Code, documents that must be available for the shareholders for the purpose of general meetings will be available at the Company's registered office, 50, Rue de Dijon, 21121 Daix, the fifteenth day prior to the Combined General Meeting.

Documents listed in Article R.22-10-23 of the French Commercial Code are available on Inventiva's website mentioned above as of tomorrow, the twenty-first day that precedes the General Meeting.

In accordance with applicable regulatory provisions:

&nbsp;&nbsp;&nbsp;&nbsp;· any
 shareholder holding registered shares may, up to the fifth day, inclusive, prior to the General
 Meeting, request these documents to be sent by the Company. For shareholders holding bearer
 shares, the exercise of this right is subject to the submission of a shareholding certificate
 delivered by their financial intermediary;

&nbsp;&nbsp;&nbsp;&nbsp;· any
 shareholder may consult these documents at the Company's registered office by sending a request
 by e-mail to the following electronic address: <u>AGIVA25012023@inventivapharma.com</u>.

**About Inventiva** 

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with NASH, mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate, has a pipeline of two preclinical programs and continues to explore other development opportunities to add to its pipeline.

Inventiva's lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva reported positive results from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and received Breakthrough Therapy and Fast Track status from the U.S. Food and Drug Administration ("FDA") for lanifibranor in the treatment of NASH.

---

| | |
|:---|:---|
| ![](tm2233812d1_ex99-3img001.jpg) | **PRESS RELEASE** |

---

Inventiva's pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva's decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is in the process of selecting an oncology development candidate for its Hippo signaling pathway program.

The Company has a scientific team of approximately 80 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). <u>www.inventivapharma.com</u>.

**Contacts** 

---

| | | |
|:---|:---|:---|
| **Inventiva**<br> Pascaline Clerc<br> VP of Global External Affairs<br> <u>media@inventivapharma.com</u><br> +1 240 620 9175 | **Brunswick Group**<br> Tristan Roquet Montegon /<br> Aude Lepreux /<br> Matthieu Benoist<br> Media relations<br> <u>inventiva@brunswickgroup.com</u><br> +33 1 53 96 83 83 | **Westwicke, an ICR Company**<br> Patricia L. Bank<br> Investor relations<br> <u>patti.bank@westwicke.com</u><br> +1 415 513-1284 |

---

---

| | |
|:---|:---|
| ![](tm2233812d1_ex99-3img001.jpg) | **PRESS RELEASE** |

---

**Important Notice**

*This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, Inventiva's pipeline and preclinical and clinical development plans, future activities, expectations, plans, growth and prospects of Inventiva and its product candidates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "would", "could", "might", "should", and "continue" and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Future events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals. Actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrolment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva's business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current COVID-19 pandemic and geopolitical events, such as the conflict between Russia and Ukraine, related sanctions and related impacts and potential impacts on the initiation, enrolment and completion of Inventiva's clinical trials on anticipated timelines and macroeconomic conditions, including global inflation and uncertain financial markets or at all. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.*

 

*Please refer to the Universal Registration Document for the year ended December 31, 2021 filed with the Autorité des Marchés Financiers on March 11, 2022, the Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 11, 2022 and the financial report for the first half of 2022 filed with the Securities and Exchange Commission on September 22, 2022 for additional information in relation to such factors, risks and uncertainties.* 

 

*All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above.*

## Exhibit 99.4

**Exhibit 99.4**

---

| | |
|:---|:---|
| ![](tm2233812d1_ex99-3img001.jpg) | **PRESS RELEASE** |

---

**Statement of total voting rights and shares forming the company's share capital as of December 19, 2022**

Article R. 22-10-23 of the French Commercial Code

Market : Euronext Paris

ISIN code / Mnemo : FR0013233012 / IVA

Web site : <u>www.inventivapharma.com</u>

---

| | | | |
|:---|:---|:---|:---|
| Date | Number of Shares <br> Outstanding | Total voting rights, <br> gross <sup>(1)</sup> | Total voting rights, <br> net <sup>(2)</sup> |
| December 19, 2022 | 42 134 169 | 55 144 801 | 55 029 868 |

---

*<sup>(1)</sup>* *The total number of gross (or "theoretical") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.*

*<sup>(2)</sup>* *The total number of net (or "exercisable at a Shareholders' Meeting") voting rights is calculated without taking into account shares for which voting rights have been suspended, i.e. treasury shares (including shares purchased under the liquidity contract). It is released in order to ensure that the public is properly informed.*

**About Inventiva** 

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with NASH, mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate, has a pipeline of two preclinical programs and continues to explore other development opportunities to add to its pipeline.

Inventiva's lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva reported positive results from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and received Breakthrough Therapy and Fast Track status from the U.S. Food and Drug Administration ("FDA") for lanifibranor in the treatment of NASH.

Inventiva's pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva's decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is in the process of selecting an oncology development candidate for its Hippo signaling pathway program.

---

| | |
|:---|:---|
| ![](tm2233812d1_ex99-3img001.jpg) | **PRESS RELEASE** |

---

The Company has a scientific team of approximately 80 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). <u>www.inventivapharma.com</u>.

**Contacts** 

---

| | | |
|:---|:---|:---|
| **Inventiva**<br> Pascaline Clerc<br> VP of Global External Affairs<br> <u>media@inventivapharma.com</u><br> +1 240 620 9175 | **Brunswick Group**<br> Tristan Roquet Montegon /<br> Aude Lepreux /<br> Matthieu Benoist<br> Media relations<br> <u>inventiva@brunswickgroup.com</u><br> +33 1 53 96 83 83 | **Westwicke, an ICR Company**<br> Patricia L. Bank<br> Investor relations<br> <u>patti.bank@westwicke.com</u><br> +1 415 513-1284 |

---

**Important Notice**

*This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, Inventiva's pipeline and preclinical and clinical development plans, future activities, expectations, plans, growth and prospects of Inventiva and its product candidates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "would", "could", "might", "should", and "continue" and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Future events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals. Actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrolment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva's business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current COVID-19 pandemic and geopolitical events, such as the conflict between Russia and Ukraine, related sanctions and related impacts and potential impacts on the initiation, enrolment and completion of Inventiva's clinical trials on anticipated timelines and macroeconomic conditions, including global inflation and uncertain financial markets or at all. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.*

 

---

| | |
|:---|:---|
| ![](tm2233812d1_ex99-3img001.jpg) | **PRESS RELEASE** |

---

 

*Please refer to the Universal Registration Document for the year ended December 31, 2021 filed with the Autorité des Marchés Financiers on March 11, 2022, the Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 11, 2022 and the financial report for the first half of 2022 filed with the Securities and Exchange Commission on September 22, 2022 for additional information in relation to such factors, risks and uncertainties.* 

 

*All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above.*